Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

DanGer Shock Trial

  • Home
  • DanGer Shock Trial
Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS
Posted inCardiology Critical Care news

Refining Patient Selection for Microaxial Flow Pumps: The DanGer Shock-like Profile as a Survival Predictor in STEMI-CS

Posted by MedXY By MedXY 12/31/2025
This study validates the DanGer Shock trial criteria in a real-world registry, demonstrating that patients matching the trial's profile have significantly better survival outcomes when treated with microaxial flow pumps compared to those who do not meet these specific clinical markers.
Read More
  • Children Born SGA Receiving Growth Hormone Have Similarly Impaired Glucose-Insulin Metabolism as Children With Obesity
  • A U-Shaped Association Between Blood mtDNA Copy Number and Risk of Type 2 Diabetes
  • Cardiogenic Shock Care Still Varies Widely Across CICUs, Especially in the Choice of Inodilators
  • Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk
  • Outcomes of Heart Failure With Reduced, Mildly Reduced, or Preserved Ejection Fraction: ESC HF III Registry
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in